Skip to content

    Max Healthcare Institute Limited

    MAXHEALTHNeutral
    Healthcare·6 Feb 2026
    Management Summary

    Max Healthcare delivered its 21st consecutive quarter of YoY growth despite seasonal softness and temporary disruptions from insurance cashless services and regulatory changes. The company continued aggressive expansion with new bed additions and geographic diversification into Western India.

    Highlights

    10

    • 21st consecutive quarter of year-on-year growth in Q3

    • Revenue increased by 10% YoY to INR 2,608 crore

    • Operating EBITDA grew by 4% YoY to INR 648 crore

    • EBITDA margin at 26.1% vs 27.3% in Q3 FY25

    • Commissioned 63 brownfield beds at Nanavati Max

    • 53 brownfield beds commissioned at Max Mohali in Q2

    • Approved expansion in Pune with 450-bed hospital by 2030

    • Approved additional 260 beds at Max Dwarka

    • Digital revenue INR 803 crore (31% of overall revenue)

    • International patient revenue INR 230 crore (14% YoY growth)

    What Changed3

    vs Q4 FY26

    Guidance items14 → 3 (-11)Risks discussed4 → 3 (-1)Q&A highlights8 → 0 (-8)

    Key financials

    Single quarter

    08 metrics
    1. 01Gross Revenue₹2,608 Cr+10%YoY
    2. 02Operating EBITDA₹648 Cr+4%YoY
    3. 03EBITDA Margin26.1%-4.4%YoY
    4. 04PAT₹344 Cr+8.9%YoY
    5. 05ARPOB77,900 rupees+3%YoY

    Segment breakdown

    INR 2,608 crore Cr Revenue
    INR 803 crore (31% of total) Cr Revenue
    INR 230 crore (9% of hospital revenue) Cr Revenue
    List

    Guidance & targets

    3
    CategoryTargetPriority
    Expansion
    Pune Hospital
    450 beds
    		High
    Capacity
    Max Dwarka Expansion
    Additional 260 beds
    		High
    Timing
    Max Smart Occupancy Certificate
    Expected by end of February
    		High

    Risks & concerns

    3
    RiskSeverity

    Seasonal softness due to lack of vector-borne diseases

    excessive unanticipated seasonal softness due to lack of vector-borne diseases and transitory external factors — Other acknowledged

    medium

    Insurance cashless services disruption

    temporary shift towards institutional patients following the disruption in cashless services with stand-alone health insurers, which was fully restored towards the end of the quarter — Other acknowledged

    medium

    CGHS pricing and GST changes impact

    discontinuation of select high-value patented chemotherapy drugs in light of the revised CGHS pricing guidelines and by the reduction in GST on drugs and consumables — Other acknowledged

    medium
    1 min read3 chapters

    Detailed Narrative

    01

    Sustained Growth Despite Headwinds

    Max Healthcare achieved its 21st consecutive quarter of YoY growth with 10% revenue growth to INR 2,608 crore and 4% EBITDA growth despite seasonal softness, insurance service disruptions, and regulatory changes affecting chemotherapy drugs and GST rates.

    02

    Aggressive Capacity Expansion Strategy

    Company commissioned 116 new beds across Nanavati Max (63) and Max Mohali (53) with margin-accretive ramp-up. Board approved major expansion plans including 450-bed Pune hospital by 2030 and additional 260 beds at Max Dwarka, reflecting strong growth confidence.

    03

    Digital and International Revenue Growth

    Digital revenue reached INR 803 crore (31% of total) with 44% YoY growth in website traffic. International patient revenue grew 14% YoY to INR 230 crore, demonstrating successful diversification strategy beyond domestic markets.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.